BioWorld Asia

May 25, 2005

Merck Licenses BioXell's TREM Receptor Programs For $150M

BioXell SpA could earn up to $150 million in milestone payments from Merck & Co. Inc., which has gained exclusive commercialization rights to BioXell's preclinical TREM (Triggering Receptors Expressed on Myeloid Cells) programs. (BioWorld International) Read More

Oxagen Brings In $59.8M; U.S. Firm As Lead Investor

South Koreans Report Step Forward In Cloning, Again

ProStrakan Wants £50M IPO In Tough UK Public Market

Actelion's Palurosan Fails In Diabetic Nephropathy

Active Biotech Bringing In SEK168M In Rights Offering

Moving Fast, Astex Cleared For Clinical Trial Of AT 7519

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...